Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulotaront in Narcolepsy-Cataplexy
NCT05015673Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ulotaront in narcolepsy (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change from baseline in the total number of cataplexy attacks at 2 weeks and Clinical Global Impression-Improvement at 2 weeks. Started Jun 2014; status: completed.
02
Drugs
ulotaront
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT05015673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015673.